Kronn, D., Davison, J., Brassier, A., Broomfield, A., Hahn, S. H., Kumada, S., … On behalf of the Mini-COMET investigators. (2022). OP016: Mini-COMET: Safety and efficacy of ≥97 weeks’ avalglucosidase alfa in infantile-onset Pompe disease participants previously treated with alglucosidase alfa. In Genetics in Medicine (Vol. 24, pp. S348–S349). Elsevier BV. https://doi.org/10.1016/j.gim.2022.01.566

Kronn, David, James Davison, Anaïs Brassier, Alexander Broomfield, Si Houn Hahn, Satoko Kumada, François Labarthe, et al. “OP016: Mini-COMET: Safety and efficacy of ≥97 weeks’ avalglucosidase alfa in infantile-onset Pompe disease participants previously treated with alglucosidase alfa.” In Genetics in Medicine, 24:S348–49. Elsevier BV, 2022. https://doi.org/10.1016/j.gim.2022.01.566.

Kronn D, Davison J, Brassier A, Broomfield A, Hahn SH, Kumada S, et al. OP016: Mini-COMET: Safety and efficacy of ≥97 weeks’ avalglucosidase alfa in infantile-onset Pompe disease participants previously treated with alglucosidase alfa. In: Genetics in Medicine. Elsevier BV; 2022. p. S348–9.

Kronn, David, et al. “OP016: Mini-COMET: Safety and efficacy of ≥97 weeks’ avalglucosidase alfa in infantile-onset Pompe disease participants previously treated with alglucosidase alfa.” Genetics in Medicine, vol. 24, no. 3, Elsevier BV, 2022, pp. S348–49. Crossref, doi:10.1016/j.gim.2022.01.566.

Kronn D, Davison J, Brassier A, Broomfield A, Hahn SH, Kumada S, Labarthe F, Ohki H, Prakalapakorn SG, Haack KA, Meng X, Sparks S, Tammireddy S, Wilson C, Zaher A, Zhou T, Chien Y-H, Kishnani P, On behalf of the Mini-COMET investigators. OP016: Mini-COMET: Safety and efficacy of ≥97 weeks’ avalglucosidase alfa in infantile-onset Pompe disease participants previously treated with alglucosidase alfa. Genetics in Medicine. Elsevier BV; 2022. p. S348–S349.